Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma : the UCLA experience

作者: Jeffrey D. Lee , Sol Perez , He-Jing Wang , Robert A. Figlin , E. Carmack Holmes

DOI: 10.1002/JSO.2930600410

关键词: Respiratory diseaseMedicineCytarabineSurgeryChemotherapyDecorticationRadiation therapyMesotheliomaCisplatinMortality rate

摘要: From 1986 to 1993, 15 patients with malignant pleural mesothelioma were treated by pleurectomy/decortication and intrapleural cisplatin (100 mg/ m2) cytosine arabinoside (1,200 mg). All without known extrathoracic disease had a mean age of 63.5 ± 7.9 years (range 51–78); 13 male. Histologic subtype epithelial (47%), sarcomatoid (27%), mixed-biphasic (27%). The major morbidity mortality rates 13% 0%, respectively. length hospital stay was 6.5 2.1 days. Postoperatively, adjuvant chemotherapy radiation therapy given 46% 73% the Median survival from date treatment 11.5 months. Those an histologic experienced significantly improved compared those (P = 0.024). Whether or no significant effect on survival. These data suggest that although this regimen can be administered very limited mortality, role approach in appears cannot currently recommended. © 1995 Wiley-Liss, Inc.

参考文章(20)
Valerie W. Rusch, Steven Piantadosi, E. Carmack Holmes, The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 102, pp. 1- 9 ,(1991) , 10.1016/S0022-5223(19)36577-8
V W Rusch, D Niedzwiecki, Y Tao, C Menendez-Botet, A Dnistrian, D Kelsen, L Saltz, M Markman, Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. Journal of Clinical Oncology. ,vol. 10, pp. 1001- 1006 ,(1992) , 10.1200/JCO.1992.10.6.1001
D J Sugarbaker, G M Strauss, T J Lynch, W Richards, S J Mentzer, T H Lee, J M Corson, K H Antman, Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma Journal of Clinical Oncology. ,vol. 11, pp. 1172- 1178 ,(1993) , 10.1200/JCO.1993.11.6.1172
A S Alberts, G Falkson, L Goedhals, D A Vorobiof, C A Van der Merwe, Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. Journal of Clinical Oncology. ,vol. 6, pp. 527- 535 ,(1988) , 10.1200/JCO.1988.6.3.527
V W Rusch, R Figlin, D Godwin, S Piantadosi, Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. Journal of Clinical Oncology. ,vol. 9, pp. 313- 319 ,(1991) , 10.1200/JCO.1991.9.2.313
P Ruffie, R Feld, S Minkin, Y Cormier, A Boutan-Laroze, R Ginsberg, J Ayoub, F A Shepherd, W K Evans, A Figueredo, Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. Journal of Clinical Oncology. ,vol. 7, pp. 1157- 1168 ,(1989) , 10.1200/JCO.1989.7.8.1157
Bergerat Jp, Drewinko B, Barlogie B, Ho Dh, Corry P, Synergistic Lethal Effect of cis-Dichlorodiammineplatinum and 1-β-D-Arabinofuranosylcytosine Cancer Research. ,vol. 41, pp. 25- 30 ,(1981)
Kasi S. Sridhar, Xaul Doria, William A. Raub, Richard J. Thurer, Mario Saldana, New strategies are needed in diffuse malignant mesothelioma Cancer. ,vol. 70, pp. 2969- 2979 ,(1992) , 10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
L. Tammilehto, P. Maasilta, S. Kostiainen, P. Appelqvist, L.R. Holsti, K. Mattson, Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration. ,vol. 59, pp. 129- 135 ,(1992) , 10.1159/000196043